Professor Tony Hunter - uncovering new cancer mechanisms
1:00pm - 2:00pm /
Monday 14th October 2024
/ Venue: Lecture Theatre 2 Life Sciences Building
Type: Seminar /
Category: Research
- Amanda Murphy
- Admission: Free
Add this event to my calendar
Click on "Create a calendar file" and your browser will download a .ics file for this event.
Microsoft Outlook: Download the file, double-click it to open it in Outlook, then click on "Save & Close" to save it to your calendar. If that doesn't work go into Outlook, click on the File tab, then on Open & Export, then Open Calendar. Select your .ics file then click on "Save & Close".
Google Calendar: download the file, then go into your calendar. On the left where it says "Other calendars" click on the arrow icon and then click on Import calendar. Click on Browse and select the .ics file, then click on Import.
Apple Calendar: The file may open automatically with an option to save it to your calendar. If not, download the file, then you can either drag it to Calendar or import the file by going to File >Import > Import and choosing the .ics file.
'A journey from tyrosine to histidine phosphorylation: uncovering new cancer mechanisms'
Professor Tony Hunter, FRS
Salk Institute, California, USA
Histidine phosphorylation, part of the so-called "hidden phosphoproteome", is a poorly characterised post-translational modification (PTM). Professor Hunter joins us to discuss his team's recent findings which, taken together, suggest that protein-histidine phosphorylation is perturbed in several different human cancer types, affording possible therapeutic opportunities.
In 1979, Professor Hunter made his crucial discovery that unchecked tyrosine phosphorylation in cancerous cells was behind their aberrant growth. Today, thanks to his work and that of many others, over 80 tyrosine kinase inhibitors have been approved for clinical use in the treatment of cancer.
Professor Tony Hunter, FRS
Salk Institute, California, USA
Histidine phosphorylation, part of the so-called "hidden phosphoproteome", is a poorly characterised post-translational modification (PTM). Professor Hunter joins us to discuss his team's recent findings which, taken together, suggest that protein-histidine phosphorylation is perturbed in several different human cancer types, affording possible therapeutic opportunities.
In 1979, Professor Hunter made his crucial discovery that unchecked tyrosine phosphorylation in cancerous cells was behind their aberrant growth. Today, thanks to his work and that of many others, over 80 tyrosine kinase inhibitors have been approved for clinical use in the treatment of cancer.